Efficacy and Safety of Ivarmacitinib, a Selective JAK1 Inhibitor, in Patients with Active Ankylosing Spondylitis: Results from an Adaptive Seamless Phase II/III Trial

IF 11.4 1区医学 Q1 RHEUMATOLOGY

Arthritis & Rheumatology Pub Date : 2025-06-12 DOI:10.1002/art.43238

Xu Liu, Liling Xu, Cheng Zhao, Shengyun Liu, Lingyun Sun, Lei Yang, Xiaoyan Xu, Rui Wu, Xiumei Liu, Jing Zhang, Shengqian Xu, Ping Zhu, Haiying Chen, Xiaoxia Wang, Changsong Lin, Jin Lin, Feng Zhan, Hua Wei, Qingchun Huang, Huaxiang Liu, Xinmei Ma, Guixiu Shi, Yuewu Lu, Xiuqin Geng, Zhenyu Jiang, Ning Zhang, Kaijiang Tang, Ronghua Zhang, Yi Zhao, Luan Xue, Shulin Song, Xiaofei Shi, Zhiyi Zhang, Pan Liu, Hui Wang, Zhanguo Li

引用次数: 0

Abstract

This randomized, double-blind, adaptive phase II/III trial aimed to evaluate the efficacy and safety of ivarmacitinib, a novel selective JAK1 inhibitor, in patients with active ankylosing spondylitis (AS).

查看原文本刊更多论文

选择性JAK1抑制剂伊瓦马替尼治疗活动性强直性脊柱炎的疗效和安全性：适应性无缝II/III期试验结果

这项随机、双盲、适应性II/III期试验旨在评估ivarmacitinib（一种新型选择性JAK1抑制剂）对活动性强直性脊柱炎（AS）患者的疗效和安全性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Arthritis & Rheumatology RHEUMATOLOGY-

CiteScore

20.90

自引率

3.00%

发文量

371

期刊介绍： Arthritis & Rheumatology is the official journal of the American College of Rheumatology and focuses on the natural history, pathophysiology, treatment, and outcome of rheumatic diseases. It is a peer-reviewed publication that aims to provide the highest quality basic and clinical research in this field. The journal covers a wide range of investigative areas and also includes review articles, editorials, and educational material for researchers and clinicians. Being recognized as a leading research journal in rheumatology, Arthritis & Rheumatology serves the global community of rheumatology investigators and clinicians.